The interest for α7 nAChRs PAMs is still alive and is evidenced by the approval of a number of activators to be advanced into clinical trials [12,13], for instance, AVL-3288, currently in phase I for the treatment of schizophrenia [14,15], or Encenicline (EVP-6124), in phase III for smoke cessation [16,17]. This evidence concerns the gene CHRNA7 and schizophrenia.